Research programme: birch pollen allergy immunotherapy - ImmunotekAlternative Names: Bet-v1 viscogel; Birch pollen viscogel; Viscogel-Bet v 1
Latest Information Update: 10 Sep 2013
At a glance
- Originator Lytix Biopharma
- Developer Immunotek SL; Lytix Biopharma; Viscogel AB
- Class Allergens; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Seasonal allergic rhinitis
Most Recent Events
- 10 Sep 2013 Early research in Seasonal allergic rhinitis in European Union (Sublingual)